https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-08-01 / Expert Opin Biol Ther 2007 Aug;7(8):1275-80
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-08-01 / Expert Opin Biol Ther 2007 Aug;7(8):1275-802007-08-01 00:00:002019-02-15 09:24:07Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-08-01 / Int. J. Cancer 2007 Aug;121(3):467-73
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-08-01 / Int. J. Cancer 2007 Aug;121(3):467-732007-08-01 00:00:002019-02-15 09:24:08Immunotherapy with dendritic cells for prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-08-01 / Int J Hyperthermia 2007 Aug;23(5):431-42
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-08-01 / Int J Hyperthermia 2007 Aug;23(5):431-422007-08-01 00:00:002007-08-01 00:00:00Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-08-01 / Int J Hyperthermia 2007 Aug;23(5):417-29
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-08-01 / Int J Hyperthermia 2007 Aug;23(5):417-292007-08-01 00:00:002007-08-01 00:00:00Benefits of superficial hyperthermia treatment planning: five case studies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-08-01 / Int J Hyperthermia 2007 Aug;23(5):451-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-08-01 / Int J Hyperthermia 2007 Aug;23(5):451-62007-08-01 00:00:002019-02-15 10:00:36Conformal radiotherapy plus local hyperthermia in patients affected by locally advanced high risk prostate cancer: preliminary results of a prospective phase II study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-07-24 / J. Natl. Cancer Inst. 2007 Aug;99(15):1188-99
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-07-24 / J. Natl. Cancer Inst. 2007 Aug;99(15):1188-992007-07-24 00:00:002020-06-23 09:34:42Role of tumor endothelium in CD4+ CD25+ regulatory T cell infiltration of human pancreatic carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-07-20 / Immunology 2007 Dec;122(4):615-22
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-07-20 / Immunology 2007 Dec;122(4):615-222007-07-20 00:00:002019-02-15 08:59:49Enhanced antitumour immunity by combined use of temozolomide and TAT-survivin pulsed dendritic cells in a murine glioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-07-15 / Cancer Res. 2007 Jul;67(14):6531-4
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-07-15 / Cancer Res. 2007 Jul;67(14):6531-42007-07-15 00:00:002007-07-15 00:00:00Development of vaccines for high-risk ductal carcinoma in situ of the breast
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-07-01 / Bull Cancer 2007 Jul;94(7 Suppl):F69-76
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-07-01 / Bull Cancer 2007 Jul;94(7 Suppl):F69-762007-07-01 00:00:002019-02-15 09:24:04[State of the art about new therapeutic vaccines in prostate cancer: dendritic cells, engineered tumor cells and recombinant virus]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-07-01 / Anticancer Res. 2007 Jul-Aug;27(4B):2121-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-07-01 / Anticancer Res. 2007 Jul-Aug;27(4B):2121-92007-07-01 00:00:002007-07-01 00:00:00Antigen loading of dendritic cells with apoptotic tumor cell-preparations is superior to that using necrotic cells or tumor lysates
